Cellectar Biosciences, Inc. Resources

News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • CLR 131
  • Clinical Trials
    • Overview
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Trial Recruiting
    • Children With Relapsed or Refractory Malignant Cancer Clinical Trial Recruiting
    • Relapsed or Refractory Multiple Myeloma Clinical Trial Active, not recruiting
  • News & Media
  • Investors
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results

May 11, 2018

Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma

May 9, 2018

Cellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat Neuroblastoma

May 2, 2018

Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Multiple Myeloma

Apr 17, 2018

Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating the Ability of its PDCs to Selectively Target a Broad Range of Tumor Cells

Apr 16, 2018

Preclinical Data Highlighting Uptake and Enhanced Anti-Tumor Effects of Cellectar’s CLR 131 in Head and Neck Cancer Presented at AACR Annual Meeting

Apr 16, 2018

Cellectar Biosciences Appoints Brian M. Posner as Chief Financial Officer

Apr 4, 2018

Cellectar Announces Issuance of U.S. Patent Covering CLR 131 Use in Multiple Myeloma

Apr 3, 2018

Cellectar Granted Seminal U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles

Mar 27, 2018

Cellectar Reports 2017 Financial Results and Provides a Corporate Update

Mar 21, 2018
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...26
    © 2021 Cellectar Biosciences, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Q&A